Instalab

Egg White (Gal d 2) IgE Test Blood

Pinpoint whether your immune system is reacting to egg white's most abundant protein, and how likely that reaction is to stick around.

Should you take a Egg White (Gal d 2) IgE test?

This test is most useful if any of these apply to you.

Reacting to Egg in the Diet
You or your child has had hives, swelling, vomiting, or breathing trouble after eating egg and want to pinpoint which protein is driving it.
Tracking Childhood Egg Allergy
Your child has been diagnosed with egg allergy and you want to know whether it is likely to resolve naturally or stick around.
Introducing Egg to an At-Risk Infant
Your baby has eczema or a family history of allergy and you want a clearer picture before starting egg in their diet.
Managing Eczema or Atopic Conditions
You have eczema, asthma, or other allergic conditions and want to understand whether egg sensitization is contributing to flares.

About Egg White (Gal d 2) IgE

If you or your child reacts to egg, or you suspect a hidden sensitization is driving eczema, hives, or stomach symptoms, knowing exactly which egg protein the immune system is targeting changes the picture. Gal d 2 IgE (ovalbumin-specific immunoglobulin E) zooms in on the single most abundant protein in egg white, and helps separate fleeting sensitization from allergy that is likely to persist for years.

This test will not replace a clinical history or a supervised food challenge, but it adds a layer of detail that whole-egg-white testing alone cannot. Used alongside other egg components, it helps you understand whether egg allergy is likely to fade or stay with you.

What This Test Actually Measures

Gal d 2 is the scientific name for ovalbumin, which makes up about 54 to 55 percent of egg white. The lab measures antibodies in your blood (called immunoglobulin E, or IgE) that specifically latch onto this one protein. These antibodies are produced by specialized immune cells called plasma cells after the immune system has encountered and reacted to egg.

When Gal d 2 IgE antibodies attach to mast cells and basophils (immune cells that sit in your skin, gut, and airways), they prime the body to release histamine and other chemicals the next time egg protein shows up. That release is what produces hives, swelling, vomiting, wheezing, or in rare cases, anaphylaxis.

Ovalbumin is heat-labile, meaning it breaks down when cooked at high temperatures. That single fact shapes how the result should be interpreted, especially when deciding whether someone can tolerate baked goods that contain egg.

How Gal d 2 Differs From Whole Egg White Testing

Standard egg white IgE testing measures antibodies against a mix of all the proteins in egg white. Gal d 2 (ovalbumin) testing isolates one specific protein. The other major egg white component, Gal d 1 (ovomucoid), behaves very differently because it survives heat.

ComponentWhat It IsHeat BehaviorClinical Signal
Gal d 1Ovomucoid (~11% of egg white)Heat-stable, survives cookingBest predictor of reactions to baked or heated egg
Gal d 2Ovalbumin (~54-55% of egg white)Heat-labile, breaks down when cookedMarker of overall sensitization and persistence risk

For diagnosing a current allergy to raw egg in children, whole egg white IgE testing has performed at least as well as Gal d 2 alone in some cohorts. Where Gal d 2 earns its place is in prognosis: it helps answer whether the allergy is likely to stick around.

What High Levels Mean for Egg Allergy Risk

Higher Gal d 2 IgE levels signal active sensitization to ovalbumin and raise the probability that an exposure to raw or undercooked egg will trigger symptoms. In a large meta-analysis of food allergy diagnostic tests, ovalbumin-specific IgE showed roughly moderate-to-high sensitivity and specificity for raw egg allergy, though performance varied across studies.

In the HealthNuts cohort, infants sensitized to multiple egg components at one year of age, including Gal d 2, had several times higher risk of persistent raw egg allergy at age four compared to those with limited component sensitization. Early Gal d 2 sensitization on its own was also associated with increased odds of persistent egg allergy.

Why Gal d 2 Cannot Predict Tolerance to Baked Egg

Many children who react to raw or lightly cooked egg can safely eat egg baked into muffins, cakes, or breads. The reason is that high heat destroys Gal d 2 (ovalbumin) and several other egg proteins. The protein that survives baking is Gal d 1 (ovomucoid), which is why Gal d 1 IgE, not Gal d 2 IgE, is the better predictor of whether someone will react to heated egg.

Multiple studies confirm this distinction. In Finnish children, Gal d 1-specific IgE separated those who reacted to heated egg from those who tolerated it, with an optimal cutoff identified around 3.7 kU/L in that cohort. Gal d 2 levels did not provide the same information because by the time egg is fully cooked, ovalbumin is largely gone from the food.

This is the most important counterintuitive finding to grasp: a high Gal d 2 IgE does not automatically mean someone cannot tolerate baked egg. It signals sensitization to a protein that gets neutralized by heat. The full picture requires component testing across Gal d 1 through Gal d 5, ideally alongside a clinical history and, when indicated, a supervised oral food challenge.

Related Conditions Where Egg White IgE Shows Up

Egg white sensitization patterns also appear in several atopic and inflammatory conditions beyond classic food allergy. In children with atopic dermatitis (a chronic itchy skin condition often called eczema), egg white sensitization helps define distinct subtypes that respond differently to treatment.

In pediatric inflammatory bowel disease, egg white IgE sensitization has been linked to specific clinical patterns including growth impairment, upper gastrointestinal involvement, and eosinophilia (elevated allergic-type white blood cells). Egg white IgE has also been used in a biomarker panel to help distinguish active eosinophilic esophagitis (a chronic allergic inflammation of the swallowing tube) from healthy controls.

Tracking Your Trend Over Time

A single Gal d 2 IgE result is a snapshot. The trajectory tells you whether the immune system is calming down or still primed. Falling egg-white IgE over months and years is one of the strongest signs that natural tolerance is developing, while flat or rising levels point to persistence.

In a follow-up study of children with confirmed egg allergy, a faster decline in egg-white-specific IgE within 12 months of diagnosis independently predicted later tolerance acquisition. A separate cohort showed that roughly two-thirds of children under two years old with egg allergy developed tolerance over five years, and the rate of antibody decline was a key signal.

Get a baseline now, retest in 6 to 12 months if you or your child are actively avoiding egg or undergoing supervised reintroduction, and at least annually after that. Pair Gal d 2 with whole egg white IgE and Gal d 1 to track both the diagnostic and prognostic story together.

When Results Can Be Misleading

A positive Gal d 2 IgE without a clear history of reacting to egg is not the same as an allergy. Sensitization without symptoms is common, especially in people with eczema, multiple food sensitizations, or high total IgE levels. Acting on a positive result alone, by removing egg from the diet without confirming the allergy, can lead to unnecessary restriction and delayed natural tolerance.

  • Atopic background: people with eczema or other allergies are more likely to test positive for food IgEs that do not cause real-world symptoms.
  • Cross-reactivity: antibodies raised against bird-related proteins can produce a positive egg white IgE without true egg allergy.
  • Assay variation: different lab platforms can give slightly different numerical results for the same sample, so trend tracking is most reliable when using the same lab over time.
  • Recent exposure or avoidance: the timing of egg in the diet and any ongoing immunotherapy can shift levels and should be noted alongside the result.

What to Do With an Unexpected Result

A positive Gal d 2 IgE in someone who has never reacted to egg should not trigger an immediate elimination diet. The next step is a conversation with an allergist (a doctor who specializes in allergic and immune conditions) who can put the result in context with your symptoms, exposure history, and family history. Companion tests worth ordering alongside this one include whole egg white IgE, Gal d 1 (ovomucoid) IgE, total IgE, and a skin prick test.

If your levels are high and you have a history of clear reactions, the allergist may recommend a supervised oral food challenge to confirm the diagnosis and clarify whether baked egg is tolerated. If your levels are falling over serial tests, the same conversation often leads to a planned reintroduction trial. The biomarker is most useful when it informs a decision, not when it stands alone.

Where the Science Is Still Open

Gal d 2 IgE testing is well established in pediatric allergy clinics but has been studied much less in adults. Most cutoffs come from children, and adult populations show more false-positive results because of background atopy and cross-reactivity. There is also no evidence that screening asymptomatic adults with Gal d 2 IgE detects early disease or changes outcomes.

If you are an adult with new or unexplained reactions after eating egg, this test is a reasonable place to start. If you have never had a reaction and have no risk factors, the result is unlikely to change what you do.

What Moves This Biomarker

Evidence-backed interventions that affect your Egg White (Gal d 2) IgE level

↓ Decrease
Oral immunotherapy with egg (gradually escalating doses under medical supervision)
Long-term egg oral immunotherapy can desensitize children with persistent egg allergy and is associated with falling pretreatment egg white and ovomucoid IgE levels in those who achieve sustained unresponsiveness. In a randomized trial of 55 children, lower pretreatment egg white IgE and ovomucoid IgE were linked to sustained unresponsiveness, and IgG4 antibodies (a non-allergic class) rose during therapy. This is a clinic-supervised treatment with real risks of allergic reaction during dose escalation.
MedicationModerate Evidence
↓ Decrease
Omalizumab (an injectable anti-IgE antibody) combined with oral immunotherapy
Adding omalizumab to oral immunotherapy in children with multiple food allergies including egg increases the reaction threshold and improves desensitization rates. In a randomized trial of 180 participants as young as one year old, 16 weeks of omalizumab was superior to placebo in raising the reaction threshold for peanut and other common food allergens. Effects on Gal d 2 IgE specifically were not isolated.
MedicationModerate Evidence
↓ Decrease
Early introduction of egg into the infant diet (around 4 to 6 months of age)
Introducing whole-egg powder from 4 months of age in infants at risk for egg allergy reduced sensitization and induced egg-specific IgG levels in a randomized trial of 319 infants, though about 8.5 percent of randomized infants did not tolerate the initial introduction. Early introduction shifts the immune trajectory toward tolerance rather than allergy.
DietModerate Evidence
↓ Decrease
Gradual graded exposure to baked or heated egg in children who tolerate it
Regular consumption of baked egg in children who pass a baked egg challenge accelerates the natural development of tolerance to less-cooked egg forms. Systematic reviews show this approach can improve egg allergy management and quality of life. Baked egg works because heating destroys ovalbumin (Gal d 2) while preserving the more heat-stable ovomucoid (Gal d 1) protein.
DietModerate Evidence

Frequently Asked Questions

References

22 studies
  1. Dang T, Peters R, Koplin J, Dharmage S, Gurrin L, Ponsonby a, Martino D, Neeland M, Tang M, Allen KAllergy2018
  2. Min T, Jeon YH, Yang H, Pyun BAllergy, Asthma & Immunology Research2013
  3. Montesinos E, Martorell a, Felix R, Cerda JCPediatric Allergy and Immunology2009
  4. Knight a, Shreffler W, Sampson H, Sicherer S, Noone S, Mofidi S, Nowak-wegrzyn aJournal of Allergy and Clinical Immunology2006